World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
77
Citations
61499
World Ranking
1783
National Ranking
879

Overview

Alan J. Korman is affiliated with VIR Biotechnology in the United States, with a research focus primarily in the fields of Immunology and Microbiology and Medicine. Their work spans various subfields including Immunology, Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Biomedical Engineering.

The scientist's research concentrates on topics related to cancer immunotherapy and biomarkers, immune cell function and interaction, immunotherapy and immune responses, as well as T-cell and B-cell immunology. Additional topics include CAR-T cell therapy research, immune cells in cancer, and monoclonal and polyclonal antibodies research.

Frequent publication venues for their work include Cancer Research, Nature Reviews Drug Discovery, Clinical Cancer Research, Journal of Clinical Investigation, and Nature Communications.

  • Cancer Research
  • Nature Reviews Drug Discovery
  • Clinical Cancer Research
  • Journal of Clinical Investigation
  • Nature Communications

Alan J. Korman has co-authored multiple works with researchers such as Mark Selby, Charles G. Drake, Pavel Strop, Joë-Marc Chauvin, and Mignane Ka.

  • Mark Selby
  • Charles G. Drake
  • Pavel Strop
  • Joë-Marc Chauvin
  • Mignane Ka

Some of the notable recent publications include:

  • The foundations of immune checkpoint blockade and the ipilimumab approval decennial, 2021, Nature Reviews Drug Discovery
  • Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, 2023, Journal of Clinical Oncology
  • IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma, 2020, Clinical Cancer Research
  • A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target, 2020, Journal of Clinical Investigation
  • Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models, 2021, Cancer Research

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

    Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  • Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

    Matthew M. Gubin;Xiuli Zhang;Heiko Schuster;Etienne Caron

  • Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

    Seng Ryong Woo;Meghan E Turnis;Monica V Goldberg;Jaishree Bankoti

  • 1 -1 HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1PD-L1

    Korman Alan J;Selby Mark J;Wang Changyu;Srinivasan Mohan

  • Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

    F. Stephen Hodi;Martin C. Mihm;Robert J. Soiffer;Frank G. Haluska

  • Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

    Mark J. Selby;John J. Engelhardt;Michael Quigley;Karla A. Henning

  • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

    Karl S. Peggs;Sergio A. Quezada;Cynthia A. Chambers;Alan J. Korman

  • TIGIT and PD-1 impair tumor antigen–specific CD8 + T cells in melanoma patients

    Joe-Marc Chauvin;Ornella Pagliano;Julien Fourcade;Zhaojun Sun

  • The class II molecules of the human and murine major histocompatibility complex.

    James F. Kaufman;Charles Auffray;Alan J. Korman;Deborah A. Shackelford

  • Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

    F. Stephen Hodi;Marcus Butler;Darryl A. Oble;Michael V. Seiden;Michael V. Seiden

  • Checkpoint blockade in cancer immunotherapy

    Alan J. Korman;Karl S. Peggs;James P. Allison

  • Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts

    Tucker Collins;Alan J. Korman;Claire T. Wake;Jeremy M. Boss

  • Evolving synergistic combinations of targeted immunotherapies to combat cancer.

    Ignacio Melero;David M. Berman;M. Angela Aznar;Alan J. Korman

  • In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.

    Changyu Wang;Kent B. Thudium;Minhua Han;Xi-Tao Wang

  • Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

    Karl S Peggs;Sergio A Quezada;Alan J Korman;James P Allison

  • The foundations of immune checkpoint blockade and the ipilimumab approval decennial

    Unknown

  • FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

    Rony Dahan;Emanuela Sega;John Engelhardt;Mark Selby

  • Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

    Jedd D. Wolchok;F. Stephen Hodi;Jeffrey S. Weber;James P. Allison

Frequent Co-Authors

Charles G. Drake
Charles G. Drake Columbia University
James P. Allison
James P. Allison The University of Texas MD Anderson Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Paul M. Harari
Paul M. Harari University of Wisconsin–Madison
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Mark J. Smyth
Mark J. Smyth QIMR Berghofer Medical Research Institute
Jon M. Wigginton
Jon M. Wigginton Bristol-Myers Squibb (Germany)
Jacquelyn A. Hank
Jacquelyn A. Hank University of Wisconsin–Madison
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career options. Many students also pursue nursing paths that complement immunology knowledge, such as accelerated nursing programs. Finding accelerated nursing programs near me offers a faster route into clinical roles while building a strong foundation in patient care.

Entry-level roles like Licensed Practical Nurse (LPN) positions provide practical experience in healthcare settings. Students looking for flexible options may explore lpn programs with easiest admission requirements, which help streamline the application process and get you started quickly.

Advancing to specialized practice, nurse practitioner degrees enhance clinical expertise. Those seeking a more accessible route can consider the easiest nurse practitioner program options available online, designed to balance quality education with manageable admission standards.

For professionals focused on mental health, psychiatric-mental health nurse practitioner (PMHNP) programs offer rewarding career paths. Choosing from the best pmhnp programs online ensures excellent clinical placement support and practical experience, which are critical for success in healthcare roles tied to immunologic and psychological well-being.

Best Scientists Citing Alan J. Korman

Trending Scientists

Recently Published Articles